Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 5 Lung Neoplasms 2 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Rectal Neoplasms 1 Noonan Syndrome 1 Neoplasms 1 Melanoma 1 Intestinal Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 EGFR-mutant Non-small Cell Lung Cancer 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Ductal 1 Bronchial Neoplasms 1 Breast Neoplasms 1 Advanced Non-small Cell Lung Cancer 1 Adenocarcinoma of Lung 1 Adenocarcinoma 1

Interventions

Carboplatin 9 Pemetrexed 7 osimertinib 5 pembrolizumab 3 entinostat 3 durvalumab 3 Radiosurgery 3 Cisplatin 3 Bevacizumab 3 selpercatinib 2 camrelizumab 2 Paclitaxel 2 Gemcitabine 2 Erlotinib Hydrochloride 2 Docetaxel 2 trametinib 1 sotorasib 1 repotrectinib 1 pralsetinib 1 patritumab 1 nazartinib 1 napabucasin 1 icotinib 1 exemestane 1 cobimetinib 1 ceralasertib 1 cemiplimab 1 capmatinib 1 atezolizumab 1 alectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Bronchial Neoplasms × nazartinib × Clear all

NCT03516214 2024-02-15

EATON

University of Cologne

Phase 1 Completed

Bronchial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡